Using GlaxoSmithKline's Cervarix vaccine to protect girls against the HPV virus that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening, scientists said on Wednesday. Researchers from Finland and the United States who published two studies in The Lancet Oncology journal found Cervarix "offers excellent protection" against two key strains of the human papillomavirus (HPV), particularly when given to young adolescent girls before they become sexually active.